A Study of LM-350 in Subjects With Advanced Solid Tumours
ConditionMalignant Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLaNova Medicines Limited
About this trial
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350.
For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Eligibility criteria
Qualifiers
Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
Participant must be ≥18 years or the legal age of consent at the time of signing the ICF.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Life expectancy ≥ 3 months.
Disqualifiers
Participate in any other clinical trial within 28 days prior to 1st dosing of LM-350.
Subjects who have received treatment with the same targeting.
History of ≥ Grade 3 late diarrhea during or after previous treatment with a topoisomerase inhibitor.
Subjects who have received the following anti-tumor treatments within the specified time periods prior to the first dosing of LM-350.
Trial design
Treatments tested in this trial
- LM-350 for injection
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov